BR112012001551A2 - profármacos de aminoácido galantamina e peptídeo e usos dos mesmos - Google Patents
profármacos de aminoácido galantamina e peptídeo e usos dos mesmosInfo
- Publication number
- BR112012001551A2 BR112012001551A2 BR112012001551A BR112012001551A BR112012001551A2 BR 112012001551 A2 BR112012001551 A2 BR 112012001551A2 BR 112012001551 A BR112012001551 A BR 112012001551A BR 112012001551 A BR112012001551 A BR 112012001551A BR 112012001551 A2 BR112012001551 A2 BR 112012001551A2
- Authority
- BR
- Brazil
- Prior art keywords
- galantamine
- amino acid
- peptide amino
- acid prodrugs
- prodrugs
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 2
- 150000001413 amino acids Chemical class 0.000 title 1
- 229960003980 galantamine Drugs 0.000 title 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22801409P | 2009-07-23 | 2009-07-23 | |
| PCT/US2010/043166 WO2011011766A1 (en) | 2009-07-23 | 2010-07-23 | Galantamine amino acid and peptide prodrugs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012001551A2 true BR112012001551A2 (pt) | 2017-07-11 |
Family
ID=42569670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012001551A BR112012001551A2 (pt) | 2009-07-23 | 2010-07-23 | profármacos de aminoácido galantamina e peptídeo e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110098278A1 (pt) |
| EP (1) | EP2456434A1 (pt) |
| JP (1) | JP2013500268A (pt) |
| KR (1) | KR20120046268A (pt) |
| CN (1) | CN102625700A (pt) |
| AU (1) | AU2010275431A1 (pt) |
| BR (1) | BR112012001551A2 (pt) |
| CA (1) | CA2768668A1 (pt) |
| MX (1) | MX2012000939A (pt) |
| RU (1) | RU2012106605A (pt) |
| WO (1) | WO2011011766A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012046062A1 (en) * | 2010-10-05 | 2012-04-12 | Shire, Llc | Use of prodrugs to avoid gi mediated adverse events |
| GB201019525D0 (en) * | 2010-11-18 | 2010-12-29 | Shire Llc | Oil-based formulations |
| WO2013035053A2 (en) * | 2011-09-09 | 2013-03-14 | Kareus Therapeutics, Sa | Novel conjugation-facilitated transport of drugs across blood brain barrier |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| CA2944019C (en) | 2014-03-25 | 2022-08-02 | Synaptec Development Llc | Treatment of autism |
| JP6738797B2 (ja) * | 2014-03-25 | 2020-08-12 | イーエムアイシーアイピーアイ・エルエルシーＥｍｉｃｉｐｉ Ｌｌｃ | レット症候群治療薬 |
| EP3142669A2 (en) | 2014-05-16 | 2017-03-22 | Synaptec Development LLC | CLEARANCE OF AMYLOID ß |
| CN115504893B (zh) * | 2022-11-18 | 2023-03-10 | 成都普康生物科技有限公司 | 一种L-谷氨酸-α-叔丁酯的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6316439B1 (en) * | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| AU1282099A (en) * | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
| CA2393301A1 (en) * | 1999-12-10 | 2001-06-21 | Bonnie Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| CZ303572B6 (cs) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Jemne rozmelnený prostredek a zpusob jeho prípravy |
| EP1777222A1 (en) * | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| US20090253654A1 (en) * | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| EP1937226A2 (en) | 2005-09-23 | 2008-07-02 | Alza Corporation | Transdermal galantamine delivery system |
| EP2091914A4 (en) * | 2006-11-08 | 2010-12-29 | Chongxi Yu | TRANSDERMAL ADMINISTRATION SYSTEMS FOR PEPTIDES AND RELATED CONNECTIONS |
| US9023860B2 (en) * | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
| DK2250163T3 (da) * | 2008-02-12 | 2012-07-16 | Bristol Myers Squibb Co | Hepatitis C-virusinhibitorer |
| BG110141A (en) * | 2008-05-23 | 2009-12-31 | "Софарма" Ад | GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE |
| AT507039A1 (de) * | 2008-06-26 | 2010-01-15 | Sanochemia Pharmazeutika Ag | Verfahren zum herstellen von hochreinen benzazepinderivaten |
-
2010
- 2010-07-23 CN CN2010800417679A patent/CN102625700A/zh active Pending
- 2010-07-23 JP JP2012521866A patent/JP2013500268A/ja active Pending
- 2010-07-23 RU RU2012106605/04A patent/RU2012106605A/ru unknown
- 2010-07-23 CA CA2768668A patent/CA2768668A1/en not_active Abandoned
- 2010-07-23 AU AU2010275431A patent/AU2010275431A1/en not_active Abandoned
- 2010-07-23 MX MX2012000939A patent/MX2012000939A/es not_active Application Discontinuation
- 2010-07-23 KR KR1020127004410A patent/KR20120046268A/ko not_active Application Discontinuation
- 2010-07-23 WO PCT/US2010/043166 patent/WO2011011766A1/en active Application Filing
- 2010-07-23 BR BR112012001551A patent/BR112012001551A2/pt not_active IP Right Cessation
- 2010-07-23 US US12/843,003 patent/US20110098278A1/en not_active Abandoned
- 2010-07-23 EP EP10738111A patent/EP2456434A1/en not_active Withdrawn
- 2010-07-23 US US13/386,335 patent/US20120184532A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012000939A (es) | 2012-06-08 |
| US20110098278A1 (en) | 2011-04-28 |
| US20120184532A1 (en) | 2012-07-19 |
| CN102625700A (zh) | 2012-08-01 |
| KR20120046268A (ko) | 2012-05-09 |
| JP2013500268A (ja) | 2013-01-07 |
| AU2010275431A1 (en) | 2012-02-23 |
| RU2012106605A (ru) | 2013-08-27 |
| EP2456434A1 (en) | 2012-05-30 |
| WO2011011766A1 (en) | 2011-01-27 |
| CA2768668A1 (en) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012001164A2 (pt) | aminoácido de carbamato e pró-fármacos de peptídeo de opioides e usos dos mesmos | |
| BRPI0922790A2 (pt) | peptídeos de ligação sparc e usos dos mesmos | |
| BRPI0923283A2 (pt) | conjugados terapêuticos de peptídeo e usos dos mesmos | |
| BRPI1015918A2 (pt) | conjugados de peptídeo multiméricos e usos dos mesmos | |
| BRPI0912225A2 (pt) | peptídeos de direcionamento lisossomais e usos dos mesmos | |
| BR112012001551A2 (pt) | profármacos de aminoácido galantamina e peptídeo e usos dos mesmos | |
| DK3061445T3 (da) | Højkoncentrerede farmaceutiske formuleringer | |
| BRPI1011404A2 (pt) | mutantes e usos dos mesmos | |
| HK1168353A1 (en) | Alkylamine substituted dicyanopyridine and amino acid ester prodrugs thereof | |
| BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
| BR112012006501A2 (pt) | polipeptídios e usos dos mesmos | |
| BR112013013167A2 (pt) | inibidores de bromodomínio e usos dos mesmos | |
| BRPI1011710A2 (pt) | lágrimas artificiais e usos trapêuticos | |
| BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
| BR112013021524A2 (pt) | micro-organismos recombinantes e usos dos mesmos | |
| BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
| BRPI1015238A2 (pt) | diamidas de azetidilina como inibidores de monoaciglicerol lipase | |
| BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| ES2769357T8 (es) | Formas farmacéuticas de apixaban | |
| BRPI1009197A2 (pt) | preparação de ácido alfa-cetopimélico | |
| BR112012002072A2 (pt) | polipeptídeos de fator ix modificados e usos dos mesmos | |
| BR112012004731A2 (pt) | peptídeos derivados de wnt10 e uso dos mesmos | |
| BR112014003774A2 (pt) | inibidores de dyrk1 e usos dos mesmos | |
| BRPI1006863A2 (pt) | composições de vacina e plasmodium purificado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |